JP2022093564A5 - - Google Patents

Download PDF

Info

Publication number
JP2022093564A5
JP2022093564A5 JP2022074648A JP2022074648A JP2022093564A5 JP 2022093564 A5 JP2022093564 A5 JP 2022093564A5 JP 2022074648 A JP2022074648 A JP 2022074648A JP 2022074648 A JP2022074648 A JP 2022074648A JP 2022093564 A5 JP2022093564 A5 JP 2022093564A5
Authority
JP
Japan
Prior art keywords
composition
seq
use according
car
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022074648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022093564A (ja
Filing date
Publication date
Priority claimed from JP2020023077A external-priority patent/JP2020072755A/ja
Application filed filed Critical
Publication of JP2022093564A publication Critical patent/JP2022093564A/ja
Publication of JP2022093564A5 publication Critical patent/JP2022093564A5/ja
Priority to JP2023130951A priority Critical patent/JP2023138812A/ja
Pending legal-status Critical Current

Links

JP2022074648A 2014-04-23 2022-04-28 キメラ抗原受容体(car)並びにその製造及び使用方法 Pending JP2022093564A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023130951A JP2023138812A (ja) 2014-04-23 2023-08-10 キメラ抗原受容体(car)並びにその製造及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461983103P 2014-04-23 2014-04-23
US201461983298P 2014-04-23 2014-04-23
US61/983,298 2014-04-23
US61/983,103 2014-04-23
JP2020023077A JP2020072755A (ja) 2014-04-23 2020-02-14 キメラ抗原受容体(car)並びにその製造及び使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020023077A Division JP2020072755A (ja) 2014-04-23 2020-02-14 キメラ抗原受容体(car)並びにその製造及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023130951A Division JP2023138812A (ja) 2014-04-23 2023-08-10 キメラ抗原受容体(car)並びにその製造及び使用方法

Publications (2)

Publication Number Publication Date
JP2022093564A JP2022093564A (ja) 2022-06-23
JP2022093564A5 true JP2022093564A5 (enExample) 2022-07-13

Family

ID=53055122

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016563936A Withdrawn JP2017514471A (ja) 2014-04-23 2015-04-23 キメラ抗原受容体(car)並びにその製造及び使用方法
JP2020023077A Pending JP2020072755A (ja) 2014-04-23 2020-02-14 キメラ抗原受容体(car)並びにその製造及び使用方法
JP2022074648A Pending JP2022093564A (ja) 2014-04-23 2022-04-28 キメラ抗原受容体(car)並びにその製造及び使用方法
JP2023130951A Pending JP2023138812A (ja) 2014-04-23 2023-08-10 キメラ抗原受容体(car)並びにその製造及び使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016563936A Withdrawn JP2017514471A (ja) 2014-04-23 2015-04-23 キメラ抗原受容体(car)並びにその製造及び使用方法
JP2020023077A Pending JP2020072755A (ja) 2014-04-23 2020-02-14 キメラ抗原受容体(car)並びにその製造及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023130951A Pending JP2023138812A (ja) 2014-04-23 2023-08-10 キメラ抗原受容体(car)並びにその製造及び使用方法

Country Status (8)

Country Link
US (3) US20170158749A1 (enExample)
EP (1) EP3134437A1 (enExample)
JP (4) JP2017514471A (enExample)
KR (1) KR20160145802A (enExample)
CN (1) CN106459924A (enExample)
AU (1) AU2015249655B2 (enExample)
CA (1) CA2945388A1 (enExample)
WO (1) WO2015164594A1 (enExample)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
ES2949648T3 (es) 2012-12-20 2023-10-02 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
FR3026744B1 (fr) 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
HUE070137T2 (hu) 2014-12-15 2025-05-28 Univ California CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor
WO2016138091A2 (en) 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
PL3268470T3 (pl) 2015-03-11 2021-06-14 Board Of Regents, The University Of Texas System Polipeptydy transpozazy i ich zastosowania
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56-Faced Antigen-Binding Proteins and Uses Thereof
IL257105B (en) 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
JP7020687B2 (ja) 2015-09-15 2022-02-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム T細胞受容体(tcr)結合抗体及びその使用
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
CN108779174B (zh) 2015-11-04 2022-11-29 希望之城公司 靶向her2的嵌合抗原受体
CN108472317A (zh) * 2015-11-09 2018-08-31 爱普瑞希斯有限公司 修饰免疫细胞及其用途
EP3407919A4 (en) * 2016-01-28 2019-09-04 The Regents of the University of California METHOD FOR THE SELECTIVE EXPANSION AND ENRICHMENT OF CELLS TRANSDUCED WITH CHIMERIC ANTIGEN RECEPTORS AND TREATMENT OF HIV INFECTION
KR20180105709A (ko) 2016-02-05 2018-09-28 시티 오브 호프 중추 신경계의 암의 치료를 위한 조작된 t 세포의 투여
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Car t細胞療法のための方法および組成物
WO2017184968A1 (en) * 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
AU2017277269C1 (en) * 2016-06-06 2024-10-31 Board Of Regents, The University Of Texas System BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof
US20200208111A1 (en) * 2016-06-09 2020-07-02 Branden S. Moriarity Genome-edited nk cell and methods of making and using
CN107523547A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
WO2017223557A1 (en) * 2016-06-24 2017-12-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Genetic re-engineering of immune cells to improve metabolic fitness for immunotherapy
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
AU2017319151B2 (en) 2016-08-30 2024-01-11 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
CA3053294A1 (en) 2017-02-13 2018-08-16 Assistance Publique - Hopitaux De Paris Method for generating t cells progenitors
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
CN107099603A (zh) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 肿瘤免疫t细胞检测试剂盒和检测方法
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
US11433098B2 (en) * 2017-07-12 2022-09-06 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of cancers harboring an H3K27M mutation
AU2018306307B2 (en) * 2017-07-25 2025-04-17 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
CN107287165A (zh) * 2017-08-23 2017-10-24 湖南开启时代生物科技有限责任公司 一种car‑t细胞的制备方法
CN109468278A (zh) * 2017-09-08 2019-03-15 科济生物医药(上海)有限公司 基因工程化的t细胞及应用
FI3688027T3 (fi) * 2017-09-29 2025-12-09 Us Health Mutatoidun p53:n tunnistavia t-solureseptoreita
CN107488738B (zh) * 2017-10-12 2020-04-28 中国医学科学院肿瘤医院 一种预测乳腺癌对曲妥珠单抗联合化疗治疗敏感性的生物标志物
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗-her2抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US20200209240A1 (en) * 2017-11-20 2020-07-02 Julius-Maximilians-Universität Würzburg Cd19cart cells eliminate myeloma cells that express very low levels of cd19
CU24558B1 (es) * 2017-11-28 2021-12-08 Ct Inmunologia Molecular Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
CN108070033A (zh) * 2017-12-12 2018-05-25 武汉波睿达生物科技有限公司 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
MX2020006015A (es) 2017-12-15 2020-10-12 Univ Leland Stanford Junior Composiciones y procedimientos para inhibir el agotamiento de celulas t.
US11672827B2 (en) 2017-12-23 2023-06-13 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
WO2019134036A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
BR112020014913A2 (pt) * 2018-01-22 2020-12-08 Seattle Children's Hospital (dba Seattle Children's Research Institute) Métodos para uso de células t car
WO2019147604A2 (en) * 2018-01-23 2019-08-01 Vanderbilt University Self-antigen specific t-cells as vacines for augmenting engraftment and stability of autologous transfer
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
SG11202008261WA (en) * 2018-03-08 2020-09-29 Rubius Therapeutics Inc Therapeutic cell systems and methods for treating cancer and infectious diseases
US20190247437A1 (en) * 2018-04-19 2019-08-15 APDN (B.V.I.), Inc. Engineered lymphocyte compositions, methods and systems
SG11202011080QA (en) 2018-05-11 2020-12-30 Crispr Therapeutics Ag Methods and compositions for treating cancer
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
CN112543651B (zh) * 2018-08-07 2023-06-02 普渡研究基金会 使car t细胞恢复活力
CN110862967A (zh) * 2018-08-27 2020-03-06 天津天锐生物科技有限公司 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
EP3844180A4 (en) 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
US20210340219A1 (en) * 2018-09-07 2021-11-04 Sotio, LLC Chimeric receptor polypeptides in combination with trans metabolism molecules modulating intracellular lactate concentrations and therapeutic uses thereof
CA3109747A1 (en) * 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CA3130671A1 (en) 2019-02-07 2020-08-13 Board Of Regents, The University Of Texas Systems Glucuronoxylomannan (gxm) receptor chimeric antigen receptors and use thereof
AU2020218615B2 (en) * 2019-02-08 2025-01-30 Biontech Cell & Gene Therapies Gmbh Treatment involving CAR-engineered T cells and cytokines
MX2021009742A (es) 2019-02-15 2021-12-10 Editas Medicine Inc Celulas asesinas naturales (nk) modificadas para inmunoterapia.
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP2022531185A (ja) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト 遺伝子改変t細胞を標的化するcd19を使用するb細胞悪性病変の同種細胞療法
CA3139965A1 (en) * 2019-06-07 2020-12-10 Ivie AIFUWA Automated t cell culture
EP3980453A4 (en) * 2019-06-07 2023-07-05 The Trustees of the University of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
JP7692897B2 (ja) 2019-09-10 2025-06-16 オブシディアン セラピューティクス, インコーポレイテッド 調節可能な制御のためのca2-il15融合タンパク質
EP4055150A4 (en) * 2019-11-06 2023-12-06 Baylor College Of Medicine METHOD FOR PRODUCING CYTOTOXIC EFFECTOR MEMORY T CELLS FOR T CELL TREATMENT OF CANCER
CN115003386A (zh) * 2019-11-27 2022-09-02 宾夕法尼亚大学董事会 产生抗cd3 scfv和细胞因子的人工抗原呈递细胞
MX2022006962A (es) * 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
GB2609103A (en) * 2020-02-25 2023-01-25 Quell Therapeutics Ltd Chimeric receptors for use in engineered cells
CN111253493B (zh) * 2020-03-05 2021-03-23 武汉科技大学 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
AU2021305234A1 (en) 2020-07-10 2023-02-09 Precigen, Inc. Fusion constructs and methods of using thereof
CN114716548B (zh) * 2021-01-05 2024-11-05 (株)爱恩德生物 抗-fgfr3抗体及其用途
US20240327889A1 (en) * 2021-04-05 2024-10-03 Victor TETS Regulation of cells and organisms
WO2022216813A1 (en) * 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
US20240293543A1 (en) 2021-06-23 2024-09-05 Editas Medicine, Inc. Engineered cells for therapy
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
JP2024536647A (ja) 2021-08-03 2024-10-07 ジェニシティー リミテッド 操作されたtcr複合体及びそれを使用する方法
WO2023021494A1 (en) * 2021-08-20 2023-02-23 Rudd Christopher E Compositions and methods for anti-virus chimeric antigen receptor
EP4504799A1 (en) 2022-04-08 2025-02-12 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
IL316101A (en) 2022-04-08 2024-12-01 Fate Therapeutics Inc Skeletal cells refer to solid tumors and their use
CN115873803B (zh) * 2022-11-28 2025-06-17 上海恩凯细胞技术有限公司 提高nk细胞存活和抗肿瘤活性的方法及应用
WO2025106453A1 (en) * 2023-11-13 2025-05-22 California Institute Of Technology Synpoptosis circuits for programmable cell death control

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
PT814838E (pt) 1995-03-08 2003-09-30 Scripps Research Inst Sistema de apresentacao de antigenio e activacao de celulas t
DE69737070T2 (de) 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
JP2009531303A (ja) 2006-03-01 2009-09-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ リンパ球枯渇剤をctlおよびサイトカインと組合せる癌処置
KR20090060450A (ko) 2006-10-04 2009-06-12 얀센 파마슈티카 엔.브이. 불활성화 인공 항원 제시 세포의 제조 및 세포 치료법에서 이들의 용도
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CA2735456C (en) * 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
CA3179835A1 (en) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
ES2649967T3 (es) * 2011-04-08 2018-01-16 Baylor College Of Medicine Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG11201509609SA (en) 2013-05-24 2015-12-30 Univ Texas Chimeric antigen receptor-targeting monoclonal antibodies
AU2014342020C1 (en) * 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof

Similar Documents

Publication Publication Date Title
JP2022093564A5 (enExample)
JP2010535713A5 (enExample)
JP2020501531A5 (enExample)
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2020525032A5 (enExample)
JP2020510422A5 (enExample)
JP2013502913A5 (enExample)
JP2020536109A5 (enExample)
JP2020508997A5 (enExample)
JP2010504755A5 (enExample)
JP2019531084A5 (enExample)
JP2018527919A5 (enExample)
JP2009505676A5 (enExample)
JP2009545325A5 (enExample)
JP2010532169A5 (enExample)
JP2009518039A5 (enExample)
JP2017522871A5 (enExample)
JP2018507188A5 (enExample)
JPWO2021139777A5 (enExample)
JP2014502955A5 (enExample)
JP2024016024A5 (enExample)
JP2020534012A5 (enExample)
JP2020522488A5 (enExample)
JP2020502233A5 (enExample)
JP2024001073A5 (enExample)